Research suggests that histone methyltransferase SETD2 plays a role in cardiometabolic heart failure with preserved ejection fraction (HFpEF). The enzyme may be involved in lipotoxic injury, although the specifics of its involvement are not entirely clear. Studies indicate that SETD2's impact on chromatin may be a key factor in the development of cardiometabolic HFpEF.